Cumberland Pharmaceuticals Inc. CPIX NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

38/100

1/6 Pass

SharesGrow Intrinsic Value

$5.57

+75.2%

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cumberland Pharmaceuticals Inc. (CPIX) has a negative trailing P/E of -16.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -6.05%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -16.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -6.05%).
Trailing Earnings Yield -6.05% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.

Overall SharesGrow Score: 37/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

38/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

FUTURE

55/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

✓

GROWTH

63/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — CPIX

Valuation Multiples

P/E (TTM)-16.5

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio1.88

P/S Ratio1.05

EV/EBITDA17.0

Per Share Data

EPS (TTM)$-0.19

Book Value / Share$1.64

Revenue / Share$2.98

FCF / Share$0.32

Yields & Fair Value

Earnings Yield-6.05%

Dividend Yield0.00%

SharesGrow IV$5.57 (+75.2%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-91.7	0.37	1.18	2.62	-
2017	-14.7	-0.02	1.83	2.85	-
2018	-13.5	1.35	1.68	2.30	-
2019	-22.4	0.46	1.55	2.31	-
2020	-13.4	3.08	0.95	1.19	-
2021	-19.8	-2.18	1.63	1.93	-
2022	-5.9	-0.10	0.90	0.78	-
2023	-4.1	-0.26	0.86	0.65	-
2024	-5.1	-1.13	1.46	0.88	-
2025	-21.0	0.36	2.39	1.34	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-0.06	$33.03M	$-944.68K	-2.9%
2017	$-0.50	$41.15M	$-7.98M	-19.4%
2018	$-0.45	$40.74M	$-6.96M	-17.1%
2019	$-0.60	$34.39M	$-9.21M	-26.8%
2020	$-0.44	$37.44M	$-6.63M	-17.7%
2021	$-0.38	$35.99M	$-5.6M	-15.6%
2022	$-0.39	$42.01M	$-5.65M	-13.4%
2023	$-0.44	$39.55M	$-6.28M	-15.9%
2024	$-0.46	$37.87M	$-6.48M	-17.1%
2025	$-0.19	$44.52M	$-2.84M	-6.4%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.55	$-0.55 – $-0.55	$38.23M	$38.23M – $38.23M	1
2027	$-0.55	$-0.55 – $-0.55	$38.23M	$38.23M – $38.23M	1
2028	$-0.31	$-0.31 – $-0.31	$45.2M	$45.2M – $45.2M	1
2029	$-0.22	$-0.22 – $-0.22	$36.96M	$36.96M – $36.96M	1
2030	$-0.03	$-0.03 – $-0.03	$40.97M	$40.97M – $40.97M	1